1. Search Result
Search Result
Results for "

NKG2A Inhibitors

" in MCE Product Catalog:
Cat. No. Product Name Target Research Areas
  • HY-P99032

    Checkpoint Kinase (Chk) IFNAR Cancer Inflammation/Immunology
    Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).